|
**Overview**: FISH PDGFR Alpha Panel**Introduction**: The FISH PDGFR Alpha Panel is a diagnostic tool designed to detect PDGFR Alpha rearrangement using whole blood or bone marrow samples. In India, PDGFR Alpha (4q12) rearrangements occur in rare myeloproliferative neoplasms with eosinophilia (e.g., 4q12 syndrome), associated with imatinib-responsive disease. High morbidity from underdiagnosis in rural/low-SES patients with persistent eosinophilia or myeloproliferation, limited FISH labs, delayed TKI therapy leading to organ damage. Per cytogenetics practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs FISH for PDGFR Alpha (4q12) rearrangement over 1-2 days with high sensitivity/specificity, valuable for molecular diagnosis in eosinophilic disorders. This diagnostic falls under genetic cancer screening and targets patients with unexplained eosinophilia or suspected myeloid neoplasm, addressing accurate detection to guide imatinib or other therapy. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise identification and improving outcomes. Its blood/bone marrow-based approach ensures reliable rearrangement detection.**Other Names**: FISH PDGFRa Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.**Historical Milestone**: PDGFRa FISH for eosinophilia; in India, reported in rare cases.**Purpose**: The test detects 2 parameters including PDGFR Alpha rearrangement to guide genetic assessment, identify actionable variants, inform therapy.**Test Parameters**: 1. PDGFR Alpha (4q12) Rearrangement, 2. Chromosomal Rearrangement.**Pretest Condition**: No fasting required; patients should have eosinophilia or suspected myeloproliferative disorder.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on eosinophil count, organ symptoms, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected rearrangement including progression, benefits of detection, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive PDGFR Alpha rearrangement indicates targetable disease, necessitating specialist input. Negative may require follow-up.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: NGS, karyotype for confirmation.**Test Limitations**: Detects specific locus; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Myeloproliferative Studies India 2023. |
